Tuberous Sclerosis, type 1

Tuberous Sclerosis, Type 1

Tuberous Sclerosis, Type 1 (TSC1) is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, leading to a variety of clinical manifestations. TSC1 is caused by mutations in the TSC1 gene, which encodes the protein hamartin.

Genetics

Tuberous Sclerosis is an autosomal dominant disorder, meaning that only one copy of the altered gene in each cell is sufficient to cause the disorder. The TSC1 gene is located on chromosome 9q34 and encodes the protein hamartin, which interacts with the protein tuberin (encoded by the TSC2 gene) to form a complex that regulates cell growth and proliferation.

Mutations in the TSC1 gene lead to a loss of function of hamartin, disrupting the hamartin-tuberin complex and resulting in the overactivation of the mTOR signaling pathway. This overactivation leads to the development of the characteristic tumors seen in TSC.

Clinical Features

Individuals with TSC1 can present with a wide range of symptoms, which may include:

• Skin lesions: These include hypomelanotic macules (ash leaf spots), facial angiofibromas, shagreen patches, and periungual fibromas.
• Neurological symptoms: Seizures are common and can be difficult to control. Other neurological manifestations include cortical tubers, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs).
• Renal involvement: Angiomyolipomas are benign tumors of the kidney that can cause complications such as bleeding.
• Cardiac rhabdomyomas: These are benign tumors of the heart that are often present at birth and may regress over time.
• Pulmonary involvement: Lymphangioleiomyomatosis (LAM) can occur, particularly in women, leading to respiratory issues.

Diagnosis

The diagnosis of TSC1 is based on clinical criteria and can be confirmed by genetic testing. The presence of characteristic skin lesions, neurological symptoms, and other organ involvement can lead to a clinical diagnosis. Genetic testing can identify mutations in the TSC1 gene, confirming the diagnosis.

Management

Management of TSC1 involves a multidisciplinary approach to address the various manifestations of the disorder. Treatment options may include:

• Antiepileptic drugs for seizure control.
• mTOR inhibitors such as everolimus to reduce the size of tumors and control symptoms.
• Surgical interventions for the removal of problematic tumors, such as SEGAs or renal angiomyolipomas.
• Regular monitoring of organ function and tumor growth.

Prognosis

The prognosis for individuals with TSC1 varies widely depending on the severity of symptoms and the organs involved. With appropriate management, many individuals can lead relatively normal lives, although some may experience significant challenges due to neurological or other complications.

Also see

• Tuberous Sclerosis Complex
• TSC2
• mTOR signaling pathway
• Genetic disorders

edit 

WikiMD neurology

External links

• Comprehensive information from the National Institute of health.
  

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z